AR011174A1 - Compuestos de pirazina, composiciones farmaceuticas que los contienen, su uso en la peparacion de medicamentos y proceso para prepararlos - Google Patents

Compuestos de pirazina, composiciones farmaceuticas que los contienen, su uso en la peparacion de medicamentos y proceso para prepararlos

Info

Publication number
AR011174A1
AR011174A1 ARP980100906A ARP980100906A AR011174A1 AR 011174 A1 AR011174 A1 AR 011174A1 AR P980100906 A ARP980100906 A AR P980100906A AR P980100906 A ARP980100906 A AR P980100906A AR 011174 A1 AR011174 A1 AR 011174A1
Authority
AR
Argentina
Prior art keywords
4alkyl
substituted
hydrogen
group
halogen atoms
Prior art date
Application number
ARP980100906A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704275.8A external-priority patent/GB9704275D0/en
Priority claimed from GBGB9708183.0A external-priority patent/GB9708183D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR011174A1 publication Critical patent/AR011174A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms

Abstract

Un compuesto de la formula (I), en la que R1 se selecciona del grupo que consiste de fenilo sustituido por uno o más átomos de halogeno, naftilo ynaftilo sustituido por uno o más átomos de halogeno; R2 se selecciona del grupo que consiste de -NH2y -NHC (=O) Ra; R3 se selecciona del grupo que consistede -RbRc, -NHC (=O)Ra e hidrogeno; R4 se selecciona del grupo que consiste de hidrogeno, -alquilo de C1-4, -alquilo de C1-4 sustituido por uno o más átomosde halogeno, -CN, -CH2OH, -CH2ORd y -C H2S(O)xRd; en la que Ra representa alquilo de C1-4 o cicloalquilo de C3-7, y Rb y Rc, los cuales pueden ser losmismos o diferentes, se seleccionan de hidrogeno y alquilo de C1-4, o junto con el átomo de nitrogeno al cual están unidos,form a un nitrogeno de 6miembros que contiene heterociclo, el cual puede ser además sustituido con uno o más de alquilo de C1-4; Rd se selecciona de alquilo de C1-4 o alquilo deC1-4 sustituido por uno o más átomos de halogeno; x es un numero enterode ce ro uno o dos; y derivados farmacéuticamente aceptables de los mismos; con lacondicion de que R1 no represente formula (II), cuando R2 sea -NH2, y ambos de R3 y R4 sean hidrogeno. Dichos compuestos y sus derivadosfarmacéuticamenteaceptables son u tiles en el tratamiento de enfermedades y trastornos o desordenes del Sistema Nervioso Central. También se describen su uso en lapreparacion de medicamentos, composiciones farmacéuticas que los contienen ymétodos para su preparacion.
ARP980100906A 1997-03-01 1998-02-27 Compuestos de pirazina, composiciones farmaceuticas que los contienen, su uso en la peparacion de medicamentos y proceso para prepararlos AR011174A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9704275.8A GB9704275D0 (en) 1997-03-01 1997-03-01 Pharmacologically active compound
GBGB9708183.0A GB9708183D0 (en) 1997-04-23 1997-04-23 Pharmacologically active compound

Publications (1)

Publication Number Publication Date
AR011174A1 true AR011174A1 (es) 2000-08-02

Family

ID=26311097

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100906A AR011174A1 (es) 1997-03-01 1998-02-27 Compuestos de pirazina, composiciones farmaceuticas que los contienen, su uso en la peparacion de medicamentos y proceso para prepararlos

Country Status (46)

Country Link
US (2) US6255307B1 (es)
EP (1) EP0966448B1 (es)
JP (1) JP3369189B2 (es)
KR (1) KR100544263B1 (es)
CN (1) CN1105111C (es)
AP (1) AP9901632A0 (es)
AR (1) AR011174A1 (es)
AT (1) ATE251143T1 (es)
AU (1) AU732915B2 (es)
BG (1) BG103723A (es)
BR (1) BR9807814B1 (es)
CA (1) CA2282585C (es)
CO (1) CO4950513A1 (es)
CZ (1) CZ295618B6 (es)
DE (1) DE69818643T2 (es)
DK (1) DK0966448T3 (es)
EA (1) EA002102B1 (es)
EE (1) EE9900376A (es)
ES (1) ES2205469T3 (es)
GE (1) GEP20012555B (es)
GT (1) GT199800046A (es)
HK (1) HK1023116A1 (es)
HN (2) HN1998000036A (es)
HR (1) HRP980107A2 (es)
HU (1) HU225852B1 (es)
ID (1) ID22850A (es)
IL (1) IL131293A (es)
IS (1) IS5163A (es)
JO (1) JO2035B1 (es)
MA (1) MA26473A1 (es)
MY (1) MY118612A (es)
NO (1) NO313383B1 (es)
NZ (1) NZ337121A (es)
OA (1) OA11151A (es)
PA (1) PA8448201A1 (es)
PE (1) PE58299A1 (es)
PL (1) PL192864B1 (es)
PT (1) PT966448E (es)
SI (1) SI0966448T1 (es)
SK (1) SK117399A3 (es)
SV (1) SV1998000029A (es)
TR (1) TR199902082T2 (es)
TW (1) TW513416B (es)
UY (1) UY24911A1 (es)
WO (1) WO1998038174A1 (es)
YU (1) YU40799A (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
GB9818881D0 (en) 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
GB9907965D0 (en) * 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
US6479498B1 (en) 1999-06-04 2002-11-12 Theravance, Inc. Sodium channel drugs and uses
WO2001060806A2 (en) * 2000-02-16 2001-08-23 Neurogen Corporation Substituted arylpyrazines
EP1500653A1 (en) * 2000-02-16 2005-01-26 Neurogen Corporation Substituted arylpyrazines
GB0010971D0 (en) * 2000-05-05 2000-06-28 Glaxo Group Ltd Process
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
EP1446387B1 (en) * 2001-11-21 2009-11-04 Pharmacia & Upjohn Company LLC Substituted aryl 1,4-pyrazine derivatives
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
EP1458386B1 (en) * 2001-12-27 2007-04-18 Ortho-McNeil Pharmaceutical, Inc. Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder
JP2005533014A (ja) 2002-04-26 2005-11-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換ピラジン誘導体
CA2496197A1 (en) 2002-08-20 2004-03-04 Neurogen Corporation 5-substituted-2-arylpyrazines as modulators of crf receptors
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
CA2514574A1 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
TW200510373A (en) * 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
CA2595855C (en) 2005-01-25 2017-07-04 Synta Pharmaceuticals Corp. Pyrazine compounds for inflammation and immune-related uses
MX2007009923A (es) * 2005-02-15 2008-03-04 Jazz Pharmaceuticals Forma farmaceutica y metodo para liberacion sostenida de un compuesto de pirazina sustituido.
NL2000284C2 (nl) * 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
WO2007083239A1 (en) * 2006-01-23 2007-07-26 Pfizer Limited Pyridine derivatives as sodium channel modulators
CA2685952C (en) * 2007-05-03 2012-03-13 Pfizer Limited N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
FR3001151B1 (fr) 2013-01-21 2016-04-08 Pf Medicament Association d'un bloqueur de courant sodique lent et d'un inhibiteur du courant if sinusal et les compositions pharmarceutiques la contenant
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EA036446B1 (ru) 2016-06-14 2020-11-11 Новартис Аг Соединения и композиции для подавления активности shp2
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
CN108101857B (zh) * 2016-11-24 2021-09-03 韶远科技（上海)有限公司 制取2-氨基-3-溴-6-氯吡嗪的可放大工艺
CN107011273A (zh) * 2017-05-04 2017-08-04 无锡捷化医药科技有限公司 一种合成6‑碘‑3‑(2,3‑二氯苯基)吡嗪‑2‑胺的方法
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN115611700A (zh) * 2022-10-11 2023-01-17 辽宁东大光明化工科技有限责任公司 一种1-溴-2,5-二氯-3-氟苯的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4402958A (en) * 1981-11-19 1983-09-06 American Cyanamid Company Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates
DE3873812D1 (de) 1987-04-07 1992-09-24 Ciba Geigy Ag 3h-1,2,3-triazolo(4,5-d)pyrimidine.
JPH08238778A (ja) * 1995-03-07 1996-09-17 Brother Ind Ltd インク噴射装置の電極形成方法

Also Published As

Publication number Publication date
EE9900376A (et) 2000-04-17
HUP0001802A2 (hu) 2001-05-28
AP9901632A0 (en) 1999-09-30
MY118612A (en) 2004-12-31
HU225852B1 (en) 2007-11-28
IS5163A (is) 1999-08-24
ATE251143T1 (de) 2003-10-15
US6599905B2 (en) 2003-07-29
HUP0001802A3 (en) 2001-07-30
TR199902082T2 (xx) 2000-04-21
CN1105111C (zh) 2003-04-09
EP0966448A1 (en) 1999-12-29
NO313383B1 (no) 2002-09-23
AU6823798A (en) 1998-09-18
HN1998000036A (es) 1999-08-23
MA26473A1 (fr) 2004-12-20
EA002102B1 (ru) 2001-12-24
EA199900687A1 (ru) 2000-04-24
BG103723A (bg) 2001-05-31
AU732915B2 (en) 2001-05-03
SV1998000029A (es) 1998-12-11
CZ311199A3 (cs) 2000-02-16
CO4950513A1 (es) 2000-09-01
CN1253551A (zh) 2000-05-17
JP3369189B2 (ja) 2003-01-20
KR20000075859A (ko) 2000-12-26
PL192864B1 (pl) 2006-12-29
US20020169172A1 (en) 2002-11-14
PL335441A1 (en) 2000-04-25
CA2282585A1 (en) 1998-09-03
SK117399A3 (en) 2000-06-12
US6255307B1 (en) 2001-07-03
DE69818643T2 (de) 2004-10-07
JO2035B1 (en) 1999-05-15
DE69818643D1 (de) 2003-11-06
GEP20012555B (en) 2001-10-25
IL131293A0 (en) 2001-01-28
UY24911A1 (es) 2000-12-29
ES2205469T3 (es) 2004-05-01
EP0966448B1 (en) 2003-10-01
PA8448201A1 (es) 2000-05-24
TW513416B (en) 2002-12-11
IL131293A (en) 2003-07-31
WO1998038174A1 (en) 1998-09-03
HRP980107A2 (en) 1998-12-31
HK1023116A1 (en) 2000-09-01
OA11151A (en) 2003-04-22
DK0966448T3 (da) 2004-02-02
SI0966448T1 (en) 2004-04-30
JP2000511203A (ja) 2000-08-29
YU40799A (sh) 2001-09-28
BR9807814B1 (pt) 2009-01-13
CA2282585C (en) 2006-06-06
PT966448E (pt) 2004-02-27
NZ337121A (en) 2001-03-30
HN1999000019A (es) 1999-08-23
GT199800046A (es) 1999-08-20
BR9807814A (pt) 2000-02-22
KR100544263B1 (ko) 2006-01-23
NO994213L (no) 1999-10-29
CZ295618B6 (cs) 2005-09-14
NO994213D0 (no) 1999-08-31
ID22850A (id) 1999-12-09
PE58299A1 (es) 1999-06-23

Similar Documents

Publication Publication Date Title
AR011174A1 (es) Compuestos de pirazina, composiciones farmaceuticas que los contienen, su uso en la peparacion de medicamentos y proceso para prepararlos
KR930702292A (ko) 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체
AR004219A1 (es) Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
ES2161418T3 (es) Compuestos de piridilfurano y de piridiltiofeno y uso farmaceutico de los mismos.
AR032467A1 (es) Derivados de piridina, procedimiento para prepararlos, el uso de dichos derivados para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
BRPI0209216B8 (pt) derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
BR9911590A (pt) Pirimidinas bicìclicas e 3,4-diidropirimidinas bicìclicas como inibidores da proliferação celular
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
SE8900192D0 (sv) Dideoxididehydrokarbocykliska nukleosider
EE200200207A (et) Kinoliiniderivaatide kasutamine vähivastase ravimi valmistamiseks, ühendite saamine ning neid sisaldavad farmatseutilised kompositsioonid
AR045040A1 (es) Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos
FR2695387B1 (fr) Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
AR022413A1 (es) Utilizacion de derivados de piridazino(4,5-b)indol-1-acetamida, para la preparacion de medicamentos destinados a las enfermedades del sistema nerviosocentral
DE3585990D1 (de) Derivate von hydroxy- oder amino-substituierten piperidinylalkylchinazolinen.
PT82897B (pt) Processo de preparacao de derivados de di-hidropiridazinona
DK122191A (da) Benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
AR021826A1 (es) COMPUESTOS DE 2- FENILPIRAN-4-ONA, PROCESOS PARA PREPARARLOS, USO DE UN COMPUESTO INTERMEDIARIO EN DICHOS, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y USO DE DICHOS COMPUESTOS Y DICHA COMPOSICIoN PARA LA FABRICACIoN DE UN MEDICAMENTO
ES2119874T3 (es) Nuevos derivados de elipticina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
FI905957A (fi) Foerfarande foer framstaellning av substituerade cyklohexener, som verkar pao det centrala nervsystemet.
DK0880520T3 (da) Benzo[c]quinolinderivater, deres fremstilling af anvendelse som 5-alfa-reduktaseinhibitorer
IT1197516B (it) Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono
ATE285771T1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
FI101300B1 (fi) Menetelmä farmakologisesti aktiivisten 1,2,3,4-tetrahydrokinoliini-6-etikkahappojohdannaisten valmistamiseksi ja välituotteena käytettävät kinoliinijohdannaiset
BR0212173A (pt) Derivado de tieno [2,3-d] pirimidina, composição farmacêutica, uso de compostos de tieno[2,3-d]pirimidina ou um sal ou solvato deste farmaceuticamente aceitáveis, e, método para tratamento de distúrbios de fertilidade em pacientes em necessidade do mesmo
AR036346A1 (es) Compuestos benzo[b]pirano[3,2h]-acridin-7-ona, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FG Grant, registration